Casale TB, et al. - The impact of patients' T2 status on responses to tiotropium Respimat add-on therapy was investigated in this study performed on patients with symptomatic asthma. Findings revealed that T2 phenotype did not impact the improvements seen in the lung function, exacerbation risk, and symptom control in patients who received tiotropium Respimat as add-on therapy to inhaled corticosteroid ± long-acting β₂-agonist.